Elexis Inc. About
Elexis Exelixis is a genomics-based drug discovery company
focused on the discovery and development of potential new drug therapies, specifically
for cancer and other proliferative diseases. Elexis' most advanced clinical
program is XL119 (becatecarin), an anticancer compound as
a potential treatment for patients with bile duct tumors. that was
in-licensed from Bristol-Myers Squibb in 2001. XL784 is the first
small molecule compound developed from their proprietary drug discovery platform
for which they have filed an investigational new drug application (IND). XL784
has completed a Phase 1 clinical trial and has demonstrated potential utility
in renal disease. More
on Exelixis Key
Statistics for Exelixis
Basic
Chart for Exelixis